Terms: = Liver cancer AND KIT, C-Kit, 3815, ENSG00000157404, CD117, SCFR, P10721 AND Staging
20 results:
1. LncRNA FOXD2-AS1 facilitates the progression of hepatocellular carcinoma by regulating TWIST1.
Chen G; Zhang WL; Zhang SM; Tang KL; Zhang Y
Eur Rev Med Pharmacol Sci; 2023 May; 27(10):4536-4543. PubMed ID: 37259735
[TBL] [Abstract] [Full Text] [Related]
2. Ligand-activated PPARδ expression promotes hepatocellular carcinoma progression by regulating the PI3K-AKT signaling pathway.
Han W; Wang N; Kong R; Bao W; Lu J
J Transl Med; 2022 Feb; 20(1):86. PubMed ID: 35151320
[TBL] [Abstract] [Full Text] [Related]
3. Association of leukotrienes and prostaglandins with splenic
Kim K; Kim SJ
Hell J Nucl Med; 2021; 24(3):228-233. PubMed ID: 34901963
[TBL] [Abstract] [Full Text] [Related]
4. Current update on molecular cytogenetics, diagnosis and management of gastrointestinal stromal tumors.
Wang MX; Devine C; Segaran N; Ganeshan D
World J Gastroenterol; 2021 Nov; 27(41):7125-7133. PubMed ID: 34887632
[TBL] [Abstract] [Full Text] [Related]
5. Serum Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Level in Patients with Hepatocellular Carcinoma.
Sripariwuth E; Piwchan S; Pongcharoen S
Asian Pac J Cancer Prev; 2021 Nov; 22(11):3521-3524. PubMed ID: 34837908
[TBL] [Abstract] [Full Text] [Related]
6. Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth.
Wu MN; Zheng WJ; Ye WX; Wang L; Chen Y; Yang J; Yao DF; Yao M
World J Gastroenterol; 2021 Jun; 27(23):3327-3341. PubMed ID: 34163115
[TBL] [Abstract] [Full Text] [Related]
7. [Application of MRI-based Radiomics Models in the Assessment of Hepatic Metastasis of Rectal cancer].
Hu SX; Yang K; Wang XR; Wen DG; Xia CC; Li X; Li ZL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):311-318. PubMed ID: 33829708
[TBL] [Abstract] [Full Text] [Related]
8. LncRNA MT1JP inhibits the malignant progression of hepatocellular carcinoma through regulating AKT.
Wu JH; Xu K; Liu JH; Du LL; Li XS; Su YM; Liu JC
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6647-6656. PubMed ID: 32633354
[TBL] [Abstract] [Full Text] [Related]
9. Hepatocellular carcinoma progression is protected by miRNA-34c-5p by regulating FAM83A.
Yu WS; Wang ZG; Guo RP; Lin ZQ; Ye ZW; Lu CL
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6046-6054. PubMed ID: 32572919
[TBL] [Abstract] [Full Text] [Related]
10. Circ_0000515 drives the progression of hepatocellular carcinoma by regulating MAPK10.
Li H; Li CM; Yuan R; Wang HB; Wei J
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6014-6022. PubMed ID: 32572915
[TBL] [Abstract] [Full Text] [Related]
11. Protective effect of the RNA-binding protein RBM10 in hepatocellular carcinoma.
Zhao Z; Li J; Shen F
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6005-6013. PubMed ID: 32572914
[TBL] [Abstract] [Full Text] [Related]
12. MicroRNA-328-3p inhibits malignant progression of hepatocellular carcinoma by regulating MMP-9 level.
Li JZ; Li J; Liu BZ
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9331-9340. PubMed ID: 31773692
[TBL] [Abstract] [Full Text] [Related]
13. Overexpressed lncRNA CDKN2B-AS1 is an independent prognostic factor for liver cancer and promotes its proliferation.
Zhuang H; Cao G; Kou C; Li D
J BUON; 2019; 24(4):1441-1448. PubMed ID: 31646789
[TBL] [Abstract] [Full Text] [Related]
14. Effects of cyclin D1 gene silencing on cell proliferation, cell cycle, and apoptosis of hepatocellular carcinoma cells.
Chen J; Li X; Cheng Q; Ning D; Ma J; Zhang ZP; Chen XP; Jiang L
J Cell Biochem; 2018 Feb; 119(2):2368-2380. PubMed ID: 28885717
[TBL] [Abstract] [Full Text] [Related]
15. Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients.
Guarino M; Di Costanzo GG; Gallotta A; Tortora R; Paneghetti L; Auriemma F; Tuccillo C; Fassina G; Caporaso N; Morisco F
Scand J Clin Lab Invest; 2017 Oct; 77(6):448-453. PubMed ID: 28609160
[TBL] [Abstract] [Full Text] [Related]
16. [A Case of a Metastatic liver Tumor from a Thymic Carcinoma Detected During a Cesarean Section].
Morinaka T; Takeuchi D; Noro A; Saotome T; Yoshimura K; Kaneko T; Miura S; Kamiya J; Ashizawa Y; Akikusa B; Ogata A
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1824-6. PubMed ID: 26805185
[TBL] [Abstract] [Full Text] [Related]
17. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract] [Full Text] [Related]
18. Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma.
Atta MM; el-Masry SA; Abdel-Hameed M; Baiomy HA; Ramadan NE
Clin Biochem; 2008 Oct; 41(14-15):1131-9. PubMed ID: 18616935
[TBL] [Abstract] [Full Text] [Related]
19. Peripheral primitive neuroectodermal tumor of the stomach in a 14-year-old boy: a case report.
Czekalla R; Fuchs M; Stölzle A; Nerlich A; Poremba C; Schaefer KL; Weirich G; Höfler H; Schneller F; Peschel C; Siewert JR; Schepp W
Eur J Gastroenterol Hepatol; 2004 Nov; 16(12):1391-400. PubMed ID: 15618851
[TBL] [Abstract] [Full Text] [Related]
20. [Basic evaluation of measurement of the serum level of squamous cell carcinoma-related antigen (SCC) and its value following irradiation of cancer of the uterine cervix].
Obata Y; Tadokoro M; Kazato S; Nishi H; Ito M; Shibata H; Mizuno K; Kawamura N; Yamaguchi T; Yoshizumi T
Gan No Rinsho; 1987 Jan; 33(1):60-4. PubMed ID: 3820601
[TBL] [Abstract] [Full Text] [Related]
